FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3091865629> ?p ?o ?g. }

• W3091865629 abstract "Abstract Background The U.S. National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™) is a library of items for assessing symptomatic adverse events by patient self-report in oncology trials. The aim of this multi-site study was to generate and linguistically validate a Dutch language version of the U.S. PRO-CTCAE for use in the Netherlands and Dutch-speaking Belgium. Methods All 124 items in the PRO-CTCAE item library were translated into Dutch using established translation procedures, including dual forward translations, reconciliation, back-translation, reconciliation of the source with the back-translation, and expert reviews. Harmonization of the translation for use in both the Netherlands and Belgium was achieved via an iterative review process in which the translations were discussed and reconciled by consensus of PRO experts, clinicians and bilingual Dutch translators. The translated PRO-CTCAE™ items were completed by a geographically-diverse sample of Dutch speaking patients from the Netherlands ( n = 40) and Belgium ( n = 60), and who were currently receiving or who had recently completed cancer-directed therapy. Patients were diverse with respect to age, sex, educational attainment, and cancer diagnosis. Cognitive debriefing, using a semi-structured interview guide, probed for comprehension and clarity of PRO-CTCAE symptom terms, attributes (e.g. frequency, severity, interference), response choices, and understanding of ‘at its worst’ and ‘in the last 7 days’. Items for which the patient data indicated possible difficulties were considered for revision. Results Three items underwent minor phrasing revision and retesting was not deemed necessary. The symptom term for stretch marks was poorly understood by 12.5% of participants, and this item was revised to include parenthetical phrasing. It was retested with 10 participants from Belgium ( n = 5) and the Netherlands ( n = 5) and demonstrated acceptable comprehension. Conclusions The Dutch language version of PRO-CTCAE has been successfully developed and linguistically validated for use in oncology studies in the Netherlands and Dutch-speaking Belgium. Extending the availability of NCI PRO-CTCAE in languages beyond English increases international consistency in the capture of Patient-Reported outcomes in patients participating in cancer clinical trials." @default.
• W3091865629 created "2020-10-15" @default.
• W3091865629 creator A5016587367 @default.
• W3091865629 creator A5021918856 @default.
• W3091865629 creator A5035294646 @default.
• W3091865629 creator A5057351356 @default.
• W3091865629 creator A5060300373 @default.
• W3091865629 creator A5061515882 @default.
• W3091865629 creator A5077313682 @default.
• W3091865629 creator A5085630351 @default.
• W3091865629 creator A5087782965 @default.
• W3091865629 date "2020-10-06" @default.
• W3091865629 modified "2023-10-17" @default.
• W3091865629 title "Dutch translation and linguistic validation of the U.S. National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™)" @default.
• W3091865629 cites W1493292566 @default.
• W3091865629 cites W1842042263 @default.
• W3091865629 cites W1976304582 @default.
• W3091865629 cites W1984045421 @default.
• W3091865629 cites W2035514720 @default.
• W3091865629 cites W2043517595 @default.
• W3091865629 cites W2087202287 @default.
• W3091865629 cites W2092692880 @default.
• W3091865629 cites W2113057788 @default.
• W3091865629 cites W2113464761 @default.
• W3091865629 cites W2133323217 @default.
• W3091865629 cites W2150540741 @default.
• W3091865629 cites W2150906637 @default.
• W3091865629 cites W2160182926 @default.
• W3091865629 cites W2238083898 @default.
• W3091865629 cites W2256194856 @default.
• W3091865629 cites W2336689415 @default.
• W3091865629 cites W2339024595 @default.
• W3091865629 cites W2400151620 @default.
• W3091865629 cites W2413118791 @default.
• W3091865629 cites W2413971556 @default.
• W3091865629 cites W2586059174 @default.
• W3091865629 cites W2600291454 @default.
• W3091865629 cites W2620925856 @default.
• W3091865629 cites W2761265752 @default.
• W3091865629 cites W2772519847 @default.
• W3091865629 cites W2891042955 @default.
• W3091865629 cites W2917197653 @default.
• W3091865629 cites W2922928465 @default.
• W3091865629 cites W2998762669 @default.
• W3091865629 cites W4230202400 @default.
• W3091865629 doi "https://doi.org/10.1186/s41687-020-00249-y" @default.
• W3091865629 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7538479" @default.
• W3091865629 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33025309" @default.
• W3091865629 hasPublicationYear "2020" @default.
• W3091865629 type Work @default.
• W3091865629 sameAs 3091865629 @default.
• W3091865629 citedByCount "4" @default.
• W3091865629 countsByYear W30918656292021 @default.
• W3091865629 countsByYear W30918656292022 @default.
• W3091865629 countsByYear W30918656292023 @default.
• W3091865629 crossrefType "journal-article" @default.
• W3091865629 hasAuthorship W3091865629A5016587367 @default.
• W3091865629 hasAuthorship W3091865629A5021918856 @default.
• W3091865629 hasAuthorship W3091865629A5035294646 @default.
• W3091865629 hasAuthorship W3091865629A5057351356 @default.
• W3091865629 hasAuthorship W3091865629A5060300373 @default.
• W3091865629 hasAuthorship W3091865629A5061515882 @default.
• W3091865629 hasAuthorship W3091865629A5077313682 @default.
• W3091865629 hasAuthorship W3091865629A5085630351 @default.
• W3091865629 hasAuthorship W3091865629A5087782965 @default.
• W3091865629 hasBestOaLocation W30918656291 @default.
• W3091865629 hasConcept C118552586 @default.
• W3091865629 hasConcept C121332964 @default.
• W3091865629 hasConcept C126322002 @default.
• W3091865629 hasConcept C138885662 @default.
• W3091865629 hasConcept C15744967 @default.
• W3091865629 hasConcept C169900460 @default.
• W3091865629 hasConcept C185592680 @default.
• W3091865629 hasConcept C197934379 @default.
• W3091865629 hasConcept C202695956 @default.
• W3091865629 hasConcept C24890656 @default.
• W3091865629 hasConcept C2777146004 @default.
• W3091865629 hasConcept C2777793932 @default.
• W3091865629 hasConcept C2779962950 @default.
• W3091865629 hasConcept C41895202 @default.
• W3091865629 hasConcept C509550671 @default.
• W3091865629 hasConcept C511192102 @default.
• W3091865629 hasConcept C512399662 @default.
• W3091865629 hasConcept C547195049 @default.
• W3091865629 hasConcept C55493867 @default.
• W3091865629 hasConcept C71924100 @default.
• W3091865629 hasConcept C75969862 @default.
• W3091865629 hasConceptScore W3091865629C118552586 @default.
• W3091865629 hasConceptScore W3091865629C121332964 @default.
• W3091865629 hasConceptScore W3091865629C126322002 @default.
• W3091865629 hasConceptScore W3091865629C138885662 @default.
• W3091865629 hasConceptScore W3091865629C15744967 @default.
• W3091865629 hasConceptScore W3091865629C169900460 @default.
• W3091865629 hasConceptScore W3091865629C185592680 @default.
• W3091865629 hasConceptScore W3091865629C197934379 @default.
• W3091865629 hasConceptScore W3091865629C202695956 @default.
• W3091865629 hasConceptScore W3091865629C24890656 @default.
• W3091865629 hasConceptScore W3091865629C2777146004 @default.
• W3091865629 hasConceptScore W3091865629C2777793932 @default.
• W3091865629 hasConceptScore W3091865629C2779962950 @default.

• next